Erratum to: Cardiovasc Drugs Ther (2016) 30:305-313
DOI 10.1007/s10557-016-6666-1
The original version of this article unfortunately contained a mistake. In the Results of the Abstract section, where it says "…compared to −6 % vs. placebo and −39 % vs. ezetimibe…" it should read "…compared to −65 % vs. placebo and −39 % vs. ezetimibe …".
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at http://dx.doi.org/10.1007/s10557-016-6666-1.
Rights and permissions
About this article
Cite this article
Rosenson, R.S., Jacobson, T.A., Preiss, D. et al. Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. Cardiovasc Drugs Ther 30, 537 (2016). https://doi.org/10.1007/s10557-016-6684-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-016-6684-z